NO20080244L - Doseringsstyring for prasugrel - Google Patents

Doseringsstyring for prasugrel

Info

Publication number
NO20080244L
NO20080244L NO20080244A NO20080244A NO20080244L NO 20080244 L NO20080244 L NO 20080244L NO 20080244 A NO20080244 A NO 20080244A NO 20080244 A NO20080244 A NO 20080244A NO 20080244 L NO20080244 L NO 20080244L
Authority
NO
Norway
Prior art keywords
prasugrel
dosage control
pharmaceutically acceptable
acceptable salt
dosage regimen
Prior art date
Application number
NO20080244A
Other languages
English (en)
Norwegian (no)
Inventor
Joseph Anthony Jakubowski
John Thomas Brandt
Nagy Alphonse Farid
Christopher David Payne
Govinda Jayanath Weerakkody
Kenneth John Winters
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20080244L publication Critical patent/NO20080244L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20080244A 2005-06-17 2008-01-14 Doseringsstyring for prasugrel NO20080244L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17
PCT/US2006/023006 WO2006138317A2 (fr) 2005-06-17 2006-06-13 Posologie pour le prasugrel

Publications (1)

Publication Number Publication Date
NO20080244L true NO20080244L (no) 2008-01-14

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080244A NO20080244L (no) 2005-06-17 2008-01-14 Doseringsstyring for prasugrel

Country Status (18)

Country Link
US (1) US20090156632A1 (fr)
EP (1) EP1893205A4 (fr)
JP (1) JP2008543853A (fr)
KR (1) KR20080016647A (fr)
CN (1) CN101198329A (fr)
AU (1) AU2006259538A1 (fr)
BR (1) BRPI0612624A2 (fr)
CA (1) CA2612315A1 (fr)
EA (1) EA200800075A1 (fr)
EC (1) ECSP078014A (fr)
GT (1) GT200600263A (fr)
IL (1) IL187486A0 (fr)
MA (1) MA29722B1 (fr)
MX (1) MX2007015430A (fr)
NO (1) NO20080244L (fr)
TN (1) TNSN07474A1 (fr)
WO (1) WO2006138317A2 (fr)
ZA (1) ZA200710769B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2008072532A1 (ja) * 2006-12-07 2010-03-25 第一三共株式会社 貯蔵安定性が改善された医薬組成物
TWI482641B (zh) 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
PL3100728T3 (pl) 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (fr) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations de prasugrel à désintégration orale
EP3106151A1 (fr) 2015-06-19 2016-12-21 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques de bromhydrate de prasugrel
WO2018167447A1 (fr) * 2017-03-14 2018-09-20 University Of Sheffield Aspirine à faible dose (1-50 mg) conjointement avec des antiagrégants plaquettaires de type ticagrelor d'anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
KR20080021152A (ko) * 2000-07-06 2008-03-06 다이이찌 산쿄 가부시키가이샤 히드로피리딘 유도체 산부가염
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
CZ297570B6 (cs) * 2000-12-25 2007-02-07 Sankyo Company, Limited Farmaceutický prípravek obsahující 2-acetoxypyridinový derivát a aspirin, které spolu pusobí v synergickém úcinku, kit jej obsahující a pouzití
EP1660183A2 (fr) * 2003-05-05 2006-05-31 Eli Lilly and Company Traitement des maladies cardiovasculaires avec une substance de formule 1 (cs 747-prasugrel; rn 150322-43-4)

Also Published As

Publication number Publication date
JP2008543853A (ja) 2008-12-04
MA29722B1 (fr) 2008-09-01
GT200600263A (es) 2007-02-23
MX2007015430A (es) 2008-02-21
US20090156632A1 (en) 2009-06-18
BRPI0612624A2 (pt) 2016-11-29
EA200800075A1 (ru) 2008-04-28
CN101198329A (zh) 2008-06-11
WO2006138317A2 (fr) 2006-12-28
AU2006259538A1 (en) 2006-12-28
WO2006138317A3 (fr) 2007-05-03
KR20080016647A (ko) 2008-02-21
ECSP078014A (es) 2008-01-23
EP1893205A2 (fr) 2008-03-05
ZA200710769B (en) 2009-09-30
EP1893205A4 (fr) 2010-06-30
IL187486A0 (en) 2008-06-05
TNSN07474A1 (en) 2009-03-17
CA2612315A1 (fr) 2006-12-28

Similar Documents

Publication Publication Date Title
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
WO2006008639A8 (fr) Traitement combine pour malignites non hematologiques par anticorps anti -ogf-1r
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
TNSN07474A1 (en) Dosage regimen for prasugrel
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
ES3062720T3 (en) Sublingual epinephrine tablets
NO20055880L (no) Memantin orale doseringsformer
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
JP2011513437A5 (fr)
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
AR036312A1 (es) Composicion farmaceutica
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
JP2005525329A5 (fr)
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
WO2007064448A3 (fr) Traitement du cancer a l'aide de fts et de 2-desoxyglucose
EP1778209B8 (fr) Methodes et compositions d'administration orale de fts
NZ703464A (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
CA2516458A1 (fr) Utilisation de composes de kahalalide pour la fabrication d'un medicament pour le traitement de psoriasis
US20070292529A1 (en) Strontium compositions and methods of treating osteoporotic conditions
TW200626133A (en) Oral medication for twice-daily administration
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
CN101396561A (zh) 含有acei的组合物在制备治疗高同型半胱氨酸血症损伤及其相关疾病的药物中的用途
CR9572A (es) Regimen de dosificacion para prasugrel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application